triazoles has been researched along with vt-464 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Adomat, H; Gleave, ME; Guns, ES; Kim, S; Mangalji, A; Moore, W; Pham, S; Toren, PJ; Zoubeidi, A | 1 |
| Bambury, RM; Rathkopf, DE | 1 |
| Abbott, DH; Bird, IM | 1 |
| Araujo, JC; Efstathiou, E; Gyftaki, R; Li-Ning-Tapia, EM; Logothetis, CJ; Lu, JF; Maity, SN; Ramachandran, S; Titus, MA; Wu, G | 1 |
| Baskin-Bey, E; Brown, VV; Eisner, JR; Figg, WD; Kindrick, JD; Madan, R; Peer, CJ; Schmidt, KT | 1 |
| Chandler, B; Eisner, J; Feng, FY; Hayes, D; Liu, M; Michmerhuizen, AR; Moubadder, L; Nyati, S; Olsen, E; Pesch, AM; Pierce, LJ; Rae, JM; Ritter, C; Santola, A; Speers, C; Spratt, D; Wahl, D; Ward, ST; Wilder-Romans, K; Zhang, A | 1 |
| Child, SA; Guengerich, FP | 1 |
| Chau, CH; Cordes, LM; Dahut, WL; Eisner, J; Figg, WD; Gulley, JL; Karzai, F; Madan, RA; Moore, WR; Owens, H; Peer, CJ; Schmidt, KT; Steinberg, SM | 1 |
| Eisner, JR; Lerner, LM; Michmerhuizen, AR; Pesch, AM; Pierce, LJ; Rae, JM; Schwartz, R; Speers, CW; Ward, C; Wilder-Romans, K; Zhang, A | 1 |
2 review(s) available for triazoles and vt-464
| Article | Year |
|---|---|
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
Topics: Androgen Receptor Antagonists; Androstadienes; Androstenes; Benzamides; Benzimidazoles; Humans; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Receptors, Androgen; Thiohydantoins; Triazoles | 2016 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Male; Naphthalenes; Prednisone; Prostate; Prostatic Neoplasms; Protective Factors; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
1 trial(s) available for triazoles and vt-464
| Article | Year |
|---|---|
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Triazoles | 2020 |
6 other study(ies) available for triazoles and vt-464
| Article | Year |
|---|---|
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
Topics: Androstenes; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Naphthalenes; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Triazoles; Xenograft Model Antitumor Assays | 2015 |
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Androgens; Animals; Biopsy; Cell Line, Tumor; Dehydroepiandrosterone; Humans; Hydrocortisone; Male; Mass Spectrometry; Mice; Mice, SCID; Naphthalenes; Neoplasm Transplantation; Precision Medicine; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Clinical Trials, Phase II as Topic; Dexamethasone; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Naphthalenes; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Triazoles | 2019 |
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Lyases; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Naphthalenes; Nitriles; Phenylthiohydantoin; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Multistep Binding of the Non-Steroidal Inhibitors Orteronel and Seviteronel to Human Cytochrome P450 17A1 and Relevance to Inhibition of Enzyme Activity.
Topics: Androgen Receptor Antagonists; Binding Sites; Enzyme Inhibitors; Humans; Hydroxylation; Imidazoles; Kinetics; Naphthalenes; Oxidation-Reduction; Protein Conformation; Steroid 17-alpha-Hydroxylase; Triazoles | 2020 |
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
Topics: Androgen Receptor Antagonists; Androgens; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Naphthalenes; Piperidines; Pyrrolidines; Radiation Tolerance; Receptors, Androgen; Receptors, Estrogen; Tamoxifen; Thiazoles; Triazoles | 2022 |